7:53 AM
 | 
Jun 29, 2018
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Cara's IV analgesic meets in Phase III for postoperative pain

Cara Therapeutics Inc. (NASDAQ:CARA) said IV CR845 met the primary and secondary endpoints in the adaptive Phase II/III CLIN3001 trial to treat postoperative pain in patients undergoing abdominal surgery.

On the primary endpoint, the 1 µg/kg dose of IV CR845 significantly improved pain relief as measured by area under the curve (AUC) of the Numeric Rating Scale (NRS) over 24 hours postsurgery vs. placebo (p=0.032)....

Read the full 304 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >